Venture firms warn R&D funding for new drugs will ‘drop off a cliff’ if Dem bill approved

A collection of venture capital funds that invest in pharma and biotech startups issued a dire warning that funding for new drugs will dry up if Democrats move forward with giving Medicare the power to negotiate drug prices for certain drugs and extend those prices to commercial plans. “Investments won’t just be reduced, it will drop off a cliff,” said John Stanford, executive director of venture capital coalition Incubate, during the briefing Wednesday in Washington, D.C.

Read the source article at Healthcare News
2021-09-16 12:45:00